Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

Blanca Ferrer Lores, MDcal Doctor, Irene Mayorga-Ruiz, Angel Alberich Bayarri, PhD, Daniella Morello-González, MDcal Doctor, Irene Pastor-Galán, MDcal Doctor, Blanca Navarro-Cubells, MD PhD, Alicia Serrano, Ana Isabel Teruel, MDcal Doctor, Rosa Dosdá-Muñoz, MD PhD, Carlos Solano, MD PhD, Luis Marti-Bonmati, MD PhD, Maria Jose Terol, MD PhD

Blood (2018) 132 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2018-99-119851

Published: 2018

Journal Articles

Clinical Progression of Chronic Lymphocytic Leukemia (CLL) Is Characterized By a Progressive Increase of the Exhausted T-Cell Phenotype and Immunosuppression Induced By Leukemic Cells

Isabel Jiménez, MSc, Sabela Bobillo, MD, Pau Abrisqueta, MD PhD, Bárbara Tazón, PhD, Carles Palacio, MD, Juan C Nieto, PhD, Júlia Carabia, MSc, Maria Jose Terol, MD PhD, Jose Garcia-Marco, MD PhD, Joan Boix, BSc, Magdalena Munuera, BSc, Lluis Puigdefàbregas, Elisa Roldán, Marta Crespo, PhD, Francesc Bosch

Blood (2017) 130 (Supplement 1): 1713.

https://doi.org/10.1182/blood.V130.Suppl_1.1713.1713

Published: 2017

Journal Articles

Development and Validation of a New Tool for the Characterization of Immunoglobulin Gene Rearrangements in Patients with Chronic Lymphocytic Leukemia By Deep Next Generation Sequencing

Azahara Fuentes, Alicia Serrano, Blanca Ferrer, MD, Blanca Navarro, MDPhD, Veronica Lendinez, Laura Olivares, Carmen Ivorra, PhD, Ana Isabel Teruel, MD, Carlos Solano, MD PhD, Maria Jose Terol, MD PhD, Javier F Chaves, PhD

Blood (2017) 130 (Supplement 1): 1714.

https://doi.org/10.1182/blood.V130.Suppl_1.1714.1714

Published: 2017

Journal Articles

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Blood (2017) 130 (Supplement 1): 1715.

https://doi.org/10.1182/blood.V130.Suppl_1.1715.1715

Published: 2017

Journal Articles

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Blood (2015) 126 (23): 3944.

https://doi.org/10.1182/blood.V126.23.3944.3944

Published: 2015

Journal Articles

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

Maria Joao Baptista, PharmD, PhD, Gustavo Tapia, MD, Ana-Maria Muñoz-Marmol, PhD, Olga Garcia, MD, Josep Muncunill, MSc, Maria-Jose Terol, MD PhD, Eva González-Barca, MD PhD, Pilar Miralles, MD PhD, Ferran Vall-Llovera, MD, Mariano Provencio, MD PhD, Miriam Moreno, MD, Juan-Manuel Sancho, MD PhD, Jose-Luis Mate, MD PhD, Evarist Feliu, MD PhD, Josep-Maria Ribera, MD PhD, Jose-Tomas Navarro, MD PhD

Blood (2015) 126 (23): 3874.

https://doi.org/10.1182/blood.V126.23.3874.3874

Published: 2015

Journal Articles

Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study

Anna Puiggros, Pau Abrisqueta, MD, Lara Nonell, Marta Bodalo, Eulalia Puigdecanet, PhD, María José Terol, MD PhD, Julio Delgado, MD PhD, Lourdes Escoda, MD, Gonzalo Blanco, Sergi Serrano, MD PhD, Francesc Bosch, MD PhD, Blanca Espinet, PhD

Blood (2014) 124 (21): 4675.

https://doi.org/10.1182/blood.V124.21.4675.4675

Published: 2014

Journal Articles

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Blood (2014) 124 (21): 2524.

https://doi.org/10.1182/blood.V124.21.2524.2524

Published: 2014

Journal Articles

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Blood (2013) 122 (21): 369.

https://doi.org/10.1182/blood.V122.21.369.369

Published: 2013

Journal Articles

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Blood (2012) 120 (21): 3949.

https://doi.org/10.1182/blood.V120.21.3949.3949

Published: 2012

Journal Articles

Different Clinical Features but Not Outcome in SLL Patients Compared to CLL,

Alejandra Martinez-Trillos, MD, Eva Gine, MD, Jordina Rovira, MD, Marcos González, MD, Maria Jose Terol, MD, Julio Delgado, MD, Maria Rozman, MD, PhD, Martha Aymerich, MD, Elias Campo, MD, Armando Lopez-Guillermo, MD, Neus Villamor, MD. PhD

Blood (2011) 118 (21): 3896.

https://doi.org/10.1182/blood.V118.21.3896.3896

Published: 2011

Journal Articles

Acadesine (Acadra‘) for Patients with Resistant/Relapsed Chronic B-Cell Lymphocytic Leukemia (B-CLL): A Multicentre Phase I/II Study.

Eric W Van Den Neste, MD, PhD, Eva Gonzalez-Barca, M.D., Ann Janssens, MD, Bruno Cazin, M.D., J. Pérez de Oteyza, M.D., Maria Jose Terol, MD, T. Auton, PhD, Andrew Saunders, M.D., Clara Campas, PhD

Blood (2009) 114 (22): 4405.

https://doi.org/10.1182/blood.V114.22.4405.4405

Published: 2009

Journal Articles

A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.

Blood (2009) 114 (22): 3.

https://doi.org/10.1182/blood.V114.22.3.3

Published: 2009

Journal Articles

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Francesc Bosch, MD, PhD, Pau Abrisqueta, MD, Neus Villamor, MD, PhD, Maria Jose Terol, MD, Josep-Maria Ribera, MD, Eva Gonzalez-Barca, MD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Yolanda Gonzalez, MD, Secundino Ferrer, MD, Felix Carbonell, MD, Lourdes Escoda, MD, Isidro Jarque, MD, Encarnacion Monzo, MD, Ana Muntañola, MD, Olga Salamero, MD, Emili Montserrat, MD

Blood (2008) 112 (11): 2097.

https://doi.org/10.1182/blood.V112.11.2097.2097

Published: 2008

Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD

Blood (2007) 110 (11): 626.

https://doi.org/10.1182/blood.V110.11.626.626

Published: 2007

Journal Articles

Study of the Expression of Angiogenic Factors and Dopaminergic Receptors: Correlation with ZAP70, CD38 and the Mutational State in Chronic Lymphocytic Leukaemia (CLL).

Pilar Eroles, PhD, Isabel Benet, MD,PhD, Isabel Marugan, MD,PhD, Ana Belen Teruel, MD,PhD, Carlos Solano, MD,PhD, Maria Jose Terol, MD,PhD

Blood (2006) 108 (11): 4928.

https://doi.org/10.1182/blood.V108.11.4928.4928

Published: 2006

Journal Articles

Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.

Juan-Manuel Sancho, MD, Josep-Maria Ribera, PhD, Albert Oriol, MD, Jesus-Maria Hernandez-Rivas, PhD, Concepcion Rivas, MD, Concepcion Bethencourt, MD, Javier Fernández-Calvo, MD, Ricardo Parody, MD, Guillermo Deben, MD, Jose-Luis Bello, MD, Josep-Maria Marti, MD, Eugenia Abella, PhD, Eloy Del-Potro, MD, Maria-Jose Terol, MD, Evarist Feliu, PhD

Blood (2005) 106 (11): 1841.

https://doi.org/10.1182/blood.V106.11.1841.1841

Published: 2005

Journal Articles

Treatment of B-CLL Cells with Bortezomib and Rituximab Reduces Cell Viability In Vitro..

Eloisa Jantus Lewintre, MSc, Elena Sarsotti, Msc, Maria Jose Terol, MD, Isabel Benet, MD, Jose A. Martinez-Climent, MD, Javier Garcia-Conde, MD

Blood (2004) 104 (11): 2798.

https://doi.org/10.1182/blood.V104.11.2798.2798

Published: 2004

NARROW

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

Clinical Progression of Chronic Lymphocytic Leukemia (CLL) Is Characterized By a Progressive Increase of the Exhausted T-Cell Phenotype and Immunosuppression Induced By Leukemic Cells

Development and Validation of a New Tool for the Characterization of Immunoglobulin Gene Rearrangements in Patients with Chronic Lymphocytic Leukemia By Deep Next Generation Sequencing

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Different Clinical Features but Not Outcome in SLL Patients Compared to CLL,

Acadesine (Acadra‘) for Patients with Resistant/Relapsed Chronic B-Cell Lymphocytic Leukemia (B-CLL): A Multicentre Phase I/II Study.

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Study of the Expression of Angiogenic Factors and Dopaminergic Receptors: Correlation with ZAP70, CD38 and the Mutational State in Chronic Lymphocytic Leukaemia (CLL).

Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.

Treatment of B-CLL Cells with Bortezomib and Rituximab Reduces Cell Viability In Vitro..

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only